Chemoprotectors, mechanisms of action and clinical applications;Les medicaments chimioprotecteurs. Mecanismes d'action et applications cliniques

Revue de Medecine Interne

Volumn 17, Issue 11, 1996, Pages 936-944

  Raymond, E ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

amifostine; chemoprotector; dextrazoxane; ORG 2766

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTINE; DIETHYLDITHIOCARBAMIC ACID; GLUTATHIONE; MERCAPTAMINE; MESNA; MITOMYCIN; PROBENECID; RAZOXANE; SODIUM THIOSULFATE;

BLADDER DISEASE; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; REVIEW; VOMITING; CHEMOPROPHYLAXIS; DRUG ANTAGONISM; DRUG COMBINATION;

AMIFOSTINE; CHEMOPREVENTION; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MESNA;

EID: 0030297317     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)88125-2     Document Type: Article

References (59)

1. 1 Muggia FM, Norris K Jr. Future of cancer chemotherapy with cisplatin. Semin Oncol 1989;16:123-8
2. 2 Gandara DR, Perez EA, Wielbe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 1991;18:49-55
3. 3 Coleman CN, Bump EA, Kramer RA. Chemical modifiers of cancer treatment. Clin Oncol 1988;6:709-33
4. 4 Coleman CN, Glover DJ, Turrisi AT. Radiation and chemotherapy sensitizers and protectors. In: Chabner, Collins, eds. Cancer chemotherapy principles and practice. Hagerstown: Lippincott Company, 1989:428-48
5. 5 Schuchter LM, Luginbuhl WE, Merepol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992;19:742-51
6. 6 Raymond E, Extra JM. Les chimioprotecteurs. La Lettre du cancérologue 1994;3:49-59
7. 7 Wasserman TH. Radiotherapeutic studies with amifostine (ethyol). Semin Oncol 1994;21:21-5
8. 8 Grdina D, Sigdestad CP. Radiation protectors: the unexpected benefits. Drug Metab Rev 1989;20:13-42
9. 9 Smoluk GD, Fahey RC, Calabro-Jones PM et al. Radioprotection of cells in culture by WR 2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988;48:3641-7
10. 10 Budd GT, Lorenzi V, Ganapathi R et al. Amifostine: potential for clinically useful cytoprotection. Support Care Cancer 1994;2:380-4
11. 11 Calabro-Jones PM, Aguilera JA, Ward JF et al. Uptake of WR 2721 deratives by cells in culture: indentification of the transported form of the drug. Cancer Res 1988;48:3634-40
12. 12 Cockcroft JR, Toy JL, Ritter JM. Lack of effect of ethyol (WR 2721) on forearm blood flow in healthy volunteers. Eur J clin Pharmacol 1993;44:103-4
13. 13 Shaw LM, Bonner HS, Turrisi A et al. Measurement of S-2 (3-aminopropyl-amino) ethanethiol (WR 1065) in blood and tissue. J Liquid Chromatogr 1986;9:845-59
14. 14 Shaw LM, Bonner H, Turrisi A et al. A liquid Chromatographic electrochemical assay for S-2-(3-aminopropylamino) ethylphosphothioate (ethyol) in human plasma. J Liquid Chromatogr 1984;7:2447-65
15. 15 Treskes M, Holwera U, Nijtams LGT et al. The reversal of cisplatin-protein interactions by modulating agent ethyol and its metabolites WR 1065 and WR 3278. Cancer ChemotherPharmacol 1992;29:467-70
16. 16 Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980;40:1519-24
17. 17 Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969;42:331-5
18. 18 Treskes M, Boven E, Holwerda U et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by ethyol in the mouse. Cancer Res 1992;52:2257-60
19. 19 Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993;72:3495-501
20. 20 Van der Vijgh WJF, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): Preclinical aspects. Semin Oncol 1994;21:2-7
21. 21 Hochster H, Narang PK, Lewis RC et al. Pharmacokinetics of cardioprotectant dexrazoxane (DZR) in advanced cancer patients. Proc Am Soc Clin Oncol 1992;11:A323
22. 22 Kligerman MM, Liu TF, Moore A, Scheffler B. Protection of normal pelvic tissues in patients with advanced rectal cancer: A randomized trial of fractionated radiation therapy +/-WR 2721. Proc Am Soc Clin Oncol 1992;11:A460
23. 23 Turrisi AT, Glover DJ, Hurwitz S et al. Final report of the phase 1 trial on single-dose WR-2721 [S-2-(3-aminopropyl-amino) ethylphosphorothioic Acid]. Cancer Treat Rep 1986;70:1389-93
24. 24 Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR 2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987;5:574-8
25. 25 Glover D, Grabelsky S, Fox K, Weiler C. Cannon L, Glick J. Clinical trials of WR 2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1988;16:1201-4
26. 26 Avril MF, Ortoli JC, Fortier-Beaulieu M et al. High dose cisplatin (C) and WR 2721 in metastatic melanoma. Proc Am Soc Clin Oncol 1992;11:A1181
27. 27 Wadler S, Beitler J, Haynes H et al. A pilot clinical trial of cisplatin (CDDP), radiation therapy (RT) and ethyol against carcinoma of the cervix (CC). Proc Am Soc Clin Oncol 1993;12:A872
28. 28 Mehta M, Storer B, Schiller JH. Phase II study of WR 2721/cisplatin/vinblastine, followed by thoracic radiation (TRT) and WR-2721, in stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993;12:A1212
29. 29 Gill I, Muggia F, Parker R et al. WR 2721 (WR) pretreatment protects against the marrow toxicity of carboplatin (CB). Proc Am Soc Clin Oncol 1992;11:A351
30. 30 Click J, Kemp G, Rose P et al. A randomized trial of cyclophosphamide and cisplatin +/-WR 2721 in the treatment of advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1992;11:A258
31. 31 Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): Clinical experiences. Semin Oncol 1994;21:8-15
32. 32 Basser R, Duggan G, Rosenthal M et al. Optimal dose ratio of ADR-529 (ICRF-187) and epirubucin. Proc Am Soc Clin Oncol 1992;11:A314
33. 33 Luginbuhi W, Tester W, Shaw L et al. One or two doses of WR-2721: does it protect patients receiving carboplatin? Proc Am Soc Clin Oncol 1992;11:A312
34. 34 Browne MJ, Clark JW, Weitberg A et al. A phase I-II study of WR 2721 and carboplatinum in patients with advanced lung and breast cancer. Proc Am Soc Clin Oncol 1993;12:A452
35. 35 Budd GT, Ganapathi R, Bauer L et al. Phase I study of WR-2721 and carboplatin. Eur J Cancer 1993;29:1122-7
36. 36 Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM. WR 2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986;4:584-8
37. 37 Shpall EJ, Stemmer SM, Hami L et al. Amifostine (WR 2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994;11:2132-7
38. 38 Glick J et al. A randomized trial of cyclophosphamide and cisplatin æ amifostine in the treatment of advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1994;13:1485
39. 39 Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12
40. 40 Poplin EA, Lorusso P, Lokich JJ et al. Randomized clinical trial of mitomycin-C with or without pretreatment with WR 2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994;33:415-9
41. 41 Douay L, Hu C, Giarratana MC et al. Ethyol protects normal hemopoietic progenitor/stem cells but not leukemic progenitors from mafosfamide toxicity: importance for bone marrow purging. Blood 1993;82:A2570
42. 42 Douay L, Hu C, Giarratana MC, Gorin NC. Comparative effects of amifostine (ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994;21:16-20
43. 43 Rogers PJC, Chan KW, Rodriguez WC, Skala JP. Effect of Amifostine (WR 2721) on cytotoxicity of pharmacological purging agents used for autologous marrow graft in acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 1992;11:A944
44. 44 Howell SB, Pfeifle CE, Wung W et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51
45. 45 DeGregorio MW, Gandara DR, Holleran WM et al. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: Preliminary pharmacologic observations. Cancer Chemother Pharmacol 1989;23:276-8
46. 2/cycle): preliminary results of a phase I trial and pharmacokinetic observations. Proc AACR 1988;7:A264
47. 47 Gandara DR, Perez EA, Lawrence HJ, DeGregorio MW. Phase I trial of high dose cisplatin plus diethyldithiocarbamate rescue: toxicity profile compared to patients receiving highdose cisplatine alone. Proc AACR 1989;30:A959
48. 48 Gandara DR, Perez EA, Hoff J, DeGregorio M. High-dose cisplatin: modulation of toxicity [Abstract]. In: 6th international symposium on platinum and other metal coordination compounds, 1991
49. 49 Rothenberg ML, Ostchega Y, Steinberg SM et al. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 1988;80:1488-92
50. 50 Borch RF, Markman M. Biochemical modulation of cisplatin toxicity. Pharmacol Ther 1989;41:371-80
51. 51 Rosenfeld CS, Weisberg SR, York RM et al. Prevention of adriamicin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187). Proc Am Soc Clin Oncol 1992;11:A74
52. 52 Weisberg SR, Rosenfeld CS, York RM et al. Dexrazoxane, (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity. Proc Am Soc Clin Oncol 1992;11:A190
53. 53 Wexler LH, Berg S, Andrich M et al. ICRF-187 reduces doxorubicin-induced cardiotoxicity with no impact on response to chemotherapy. Proc Am Soc Clin Oncol 1993;12:A1434
54. 54 Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 (Cardioxane) protection against doxorubicin-induced cardiac toxicity - ratio and support from clinical trial: the NYU experience. Clinical application of ICRF-187 (Cardioxane) meeting 26 October 1991, Pisa, Italy
55. 55 Feldmann JE, Jones SE, Weisberg SR et al. Advanced small cell lung cancer treated with CAV (cyclophosphamide + adiamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). Proc Am Soc Clin Oncol 1992;11:A993
56. 56 Eliason JF, Inoue T, Kubota A et al. The anti-tumor arotinoid RO 40-8757 protects bone marrow from toxic effects of cyclophosphamide. Int J Cancer 1993;55:492-7
57. 57 Neta R, Douches S, Oppenheim JJ. Interleukin-1 is a radioprotector. J Immunol 1986;136:2483
58. 58 Smith JW, Longo DL, Alvord WG et al. The effects od treatment with Interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993;328:756-61
59. 59 Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD4+ subpopulations in response to growth factors. Blood 1993;11:3307-14